The public, healthcare practitioners, importers and distributors are informed that registrations of Grand-Pa Headache products (Powder and tablets) have been suspended from the Botswana market with immediate effect. This follows a decision by the Market Authorization Holder GlaxoSmithKline CH South Africa to temporarily halt the supply of these products to Botswana and other markets. This means that importation of new stock into the country is prohibited, however, the stock currently available in Botswana may be used.